Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimer’s disease
Open Access
- 10 February 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 26 (8) , 1483-1496
Abstract
The objective of our study was to better understand the protective effects of the mitochondria-targeted tetra-peptide SS31 against amyloid beta (Aβ)-induced mitochondrial and synaptic toxicities in Alzheimer’s disease (AD) progression. Using intraperitoneal injections, we administered SS31 to an AD mouse model (APP) over a period of 6 weeks, beginning when the APP mice were 12 months of age. We studied their cortical tissues after SS31 treatment and determined that SS31 crosses the blood brain barrier and reaches mitochondrial sites of free radical production. We also determined: (1) plasma and brain levels of SS31, (2) mRNA levels and levels of mitochondrial dynamics, biogenesis proteins and synaptic proteins, (3) soluble Aβ levels and immunoreactivity of mutant APP and Aβ levels and (4) mitochondrial function by measuring H2O2, lipid peroxidation, cytochrome c oxidase activity and mitochondrial ATP. We found reduced mRNA expression and reduced protein levels of fission genes, and increased levels of mitochondrial fusion, biogenesis and synaptic genes in SS31-treated APP mice relative to SS31-untreated APP mice. Immunofluorescence analysis revealed reduced full-length mutant APP and soluble/insoluble Aβ levels in the SS31-treated APP mice. Sandwich ELISA assays revealed significantly reduced soluble Aβ levels in the SS31-treated APP mice relative to the untreated APP mice. Mitochondrial function was maintained in the SS31-treated APP mice over the 6 weeks of SS31 treatment compared with mitochondrial function in the untreated APP mice. Our findings indicate that SS31 treatment reduces Aβ production, reduces mitochondrial dysfunction, maintains mitochondrial dynamics and enhances mitochondrial biogenesis and synaptic activity in APP mice; and that SS31 may confer protective effects against mitochondrial and synaptic toxicities in APP transgenic mice.Keywords
This publication has 66 references indexed in Scilit:
- Mitochondria-Targeted Antioxidant SS31 Prevents Amyloid Beta-Induced Mitochondrial Abnormalities and Synaptic Degeneration in Alzheimer’s DiseasePharmaceuticals, 2012
- Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: Implications to mitochondria-targeted antioxidant therapeuticsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Elevation of glutathione as a therapeutic strategy in Alzheimer diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Mitochondrial Abnormalities in Alzheimer’s Disease2012
- Assessment of newly synthesized mitochondrial DNA using BrdU labeling in primary neurons from Alzheimer's disease mice: Implications for impaired mitochondrial biogenesis and synaptic damageBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2011
- Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease miceProceedings of the National Academy of Sciences, 2009
- Amyloid-β overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteinsProceedings of the National Academy of Sciences, 2008
- Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's diseaseTrends in Molecular Medicine, 2008
- Pathways towards and away from Alzheimer's diseaseNature, 2004
- Oxidative damage in Alzheimer'sNature, 1996